Search

Displaying results 5651 - 5660 of 9333 in total
  1. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  2. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: K-O-T Standardized Grass Pollen Mix, K-O-T Standardized Grass Pollen MixProducts: GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT 100 TABLET, GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT TABLET, 30 ADET
  3. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  4. Drug

    Vicasinabin

    go.drugbank.com/drugs/DB21587
    Investigational

    Vicasinabin is under investigation in clinical trial NCT04265261 (A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic

  5. Drug

    Serelaxin

    go.drugbank.com/drugs/DB05794
    Investigational

    Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic … bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy.

  6. Drug

    Aprobarbital

    go.drugbank.com/drugs/DB01352
    ExperimentalIllicit

    Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. … A primary treatment indicated for the use of aprobarbital was subsequently insomnia.

  7. Drug

    PEG-uricase

    go.drugbank.com/drugs/DB05321
    Investigational

    of severe, treatment-refractory gout in the United States in 2006. … PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment

  8. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.

  9. Drug

    Diminazene

    go.drugbank.com/drugs/DB03608
    Experimental

    This compound belongs to the phenylhydrazines. These are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent attached to a phenyl group.

  10. Drug

    VSF-173

    go.drugbank.com/drugs/DB05753
    Investigational

    It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.